Declining intracellular T-lymphocyte concentration of cyclosporine A precedes acute rejection in kidney transplant recipients

Transplantation

Volumn 85, Issue 2, 2008, Pages 179-184

  Falck, Pål ^a   Åsberg, Anders ^a   Guldseth, Heidi ^a   Bremer, Sara ^b   Akhlaghi, Fatemeh ^c   Reubsaet, Jan L E ^a   Pfeffer, Per ^b   Hartmann, Anders ^b   Midtvedt, Karsten ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Acute rejection; Cyclosporine A; Intracellular concentration; Renal transplantation; T lymphocytes

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL ISOLATION; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; GENOTYPE; GRAFT RECIPIENT; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE;

ADULT; AGED; CYCLOSPORINE; FEMALE; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PILOT PROJECTS; T-LYMPHOCYTES;

EID: 38549095084     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31815feede     Document Type: Article

References (30)

1. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Sem Nephrol 2003; 23: 465.
2. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789.
3. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903.
4. Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: Results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577.
5. Perner F. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
6. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55.
7. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: A systematic review. Transplantation 2007; 83: 1525.
8. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
9. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
10. Batiuk TD, Pazderka F, Enns J, et al. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 1995; 96: 1254.
11. Barbari AG, Masri MA, Stephan AG, et al. Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: A prospective study. Exp Clin Transplant 2006; 4: 400.
12. Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997; 44: 537.
13. von Ahsen N, Helmhold M, Schutz E, et al. Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: Implications for therapeutic drug monitoring of cyclosporin A. Therap Drug Monitor 1997; 19: 140.
14. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735.
15. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal Pglycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Therap 1997; 62: 248.
16. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077.
17. Gotzl M, Wallner J, Gsur A, et al. MDR1 gene expression in lymphocytes of patients with renal transplants. Nephron 1995; 69: 277.
18. Falck P, Guldseth H, Asberg A, et al. Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatography B 2007; 852: 345.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
20. Berhanu D, Mortari F, De Rosa SC, Roederer M. Optimized lymphocyte isolation methods for analysis of chemokine receptor expression. J Immunol Meth 2003; 279: 199.
21. Goldberg H, Ling V, Wong PY, Skorecki K. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 1988; 152: 552.
22. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169.
23. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
24. Barbari A, Masri MA, Stephan A, et al. Cyclosporine lymphocyte versus whole blood pharmacokinetic monitoring: Correlation with histological findings. Transplant Proc 2001; 33: 2782.
25. Barbari AG, Masri MA, Stephan AG, et al. Cyclosporine lymphocyte maximum level: A new alternative for cyclosporine monitoring in kidney transplantation. Exp Clin Transplant 2005; 3: 293.
26. Collins DP. Cytokine and cytokine receptor expression as a biological indicator of immune activation: Important considerations in the development of in vitro model systems. J Immunol Meth 2000; 243: 125.
27. Masri MA, Barbari A, Stephan A, et al. Measurement of lymphocyte cyclosporine levels in transplant patients. Transplant Proc 1998; 30: 3561.
28. Donnenberg VS, Burckart GJ, Zeevi A, et al. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection. Transplantation 2004; 77: 1699.
29. Meaden ER, Hoggard PG, Khoo SH, Back DJ. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Meth 2002; 262: 159.
30. Parasrampuria DA, Lantz MV, Birnbaum JL, et al. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: A preliminary evaluation. J Clin Pharmacol 2002; 42: 304.